Online inquiry

IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12784MR)

This product GTTS-WQ12784MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets NOTCH2&NOTCH3 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001200001.2; NM_000435.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4853; 4854
UniProt ID Q04721; Q9UM47
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12784MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8552MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Hu5A8
GTTS-WQ8184MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ14146MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ10246MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ14531MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ9090MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ582MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ996MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-383
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW